Our VP of Product Portfolio and Innovation, Dr. Michael Fiebig, recently gave a presentation as part of a webinar series on the applications and benefits of animal-free recombinant antibodies. The webinar series was organized by the US National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), the PETA International Science Consortium Ltd., and the European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM).
Dr. Fiebig’s talk describes how antibody sequencing of existing hybridoma and ascites-derived antibodies allows them to be produced recombinantly, without the use of animals or animal components. In the presentation, he explains why the scientific community is “falling out of love with hybridomas” and instead moving toward recombinant antibody expression for improved batch-to-batch reproducibility, alleviation of animal welfare concerns, and the enabling of antibody engineering. The movement has been gaining more and more traction in recent years, as supported by a recent letter on animal-free antibody alternatives published in Nature Biotechnology.
At Absolute Antibody, we offer antibody sequencing services to convert existing antibodies to recombinant production, as well as recombinant expression services and a reagents catalog of animal-free recombinant antibodies and proteins. To learn more about our approach, check out our Animal-Free Antibodies page.
Below, listen to the full presentation, called Accessibility of Recombinant Antibodies:
hubXchange | Antibody Therapeutics USA West
20th September 2022
San Fransisco, CA